The Oncotype DX Genomic Prostate Score test was developed to help men with early-stage cancer and their loved ones make a more informed decision when selecting the most appropriate treatment for their disease. The information on this website is designed to help them better understand their treatment options. If you are interested in other prostate cancer topics, such as research, education, advocacy or support, please consult these resources.
If you have metastatic castration-resistant prostate cancer (mCRPC), you may be interested in learning more about a test that can help your doctor make sure you are getting the right treatment at the right time. For more information, and to see if you are eligible for this test, please consult Oncotype DX AR-V7 Nucleus Detect test.